Kodiak Sciences Shares Drop After Wider-Than-Expected 1Q Loss

Dow Jones

May 16

By Chris Wack

Kodiak Sciences shares were 21% lower, at $3.13, after the company reported a first-quarter loss that was wider than expected.

The biopharmaceutical company said it had a quarterly loss of $57.5 million, or $1.09 a share, compared with a loss of $43 million, or 82 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $48.7 million, or 86 cents a share.

The net loss for the first quarter included non-cash stock-based compensation of $15.9 million, as compared to $18.4 million last year.

Kodiak ended the quarter with $138.9 million of cash and cash equivalents, and said it believes it will support current and planned operations into 2026.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

May 15, 2025 13:41 ET (17:41 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535287943"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535287943\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535287943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 01:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535287943","market":"sh","top_or_hot":-1,"title":"Kodiak Sciences Shares Drop After Wider-Than-Expected 1Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Kodiak Sciences shares were 21% lower, at $3.13, after the company reported a first-quarter loss that was wider than expected. \n</p>\n<p>\n  The biopharmaceutical company said it had a quarterly loss of $57.5 million, or $1.09 a share, compared with a loss of $43 million, or 82 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $48.7 million, or 86 cents a share. \n</p>\n<p>\n  The net loss for the first quarter included non-cash stock-based compensation of $15.9 million, as compared to $18.4 million last year. \n</p>\n<p>\n  Kodiak ended the quarter with $138.9 million of cash and cash equivalents, and said it believes it will support current and planned operations into 2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2025 13:41 ET (17:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kodiak Sciences Shares Drop After Wider-Than-Expected 1Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKodiak Sciences Shares Drop After Wider-Than-Expected 1Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-16 01:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Kodiak Sciences shares were 21% lower, at $3.13, after the company reported a first-quarter loss that was wider than expected. \n</p>\n<p>\n  The biopharmaceutical company said it had a quarterly loss of $57.5 million, or $1.09 a share, compared with a loss of $43 million, or 82 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $48.7 million, or 86 cents a share. \n</p>\n<p>\n  The net loss for the first quarter included non-cash stock-based compensation of $15.9 million, as compared to $18.4 million last year. \n</p>\n<p>\n  Kodiak ended the quarter with $138.9 million of cash and cash equivalents, and said it believes it will support current and planned operations into 2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2025 13:41 ET (17:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KOD","symbol_name":"Kodiak Sciences Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535287943","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535287943","pubTimestamp":1747330860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Kodiak Sciences shares were 21% lower, at $3.13, after the company reported a first-quarter loss that was wider than expected.The biopharmaceutical company said it had a quarterly loss of $57.5 million, or $1.09 a share, compared with a loss of $43 million, or 82 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $48.7 million, or 86 cents a share.The net loss for the first quarter included non-cash stock-based compensation of $15.9 million, as compared to $18.4 million last year.Kodiak ended the quarter with $138.9 million of cash and cash equivalents, and said it believes it will support current and planned operations into 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KOD":"Kodiak Sciences Inc.","BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"科迪亚克科学公司第一季度亏损超出预期后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Kodiak Sciences shares were 21% lower, at $3.13, after the company reported a first-quarter loss that was wider than expected. \n\n\n  The biopharmaceutical company said it had a quarterly loss of $57.5 million, or $1.09 a share, compared with a loss of $43 million, or 82 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $48.7 million, or 86 cents a share. \n\n\n  The net loss for the first quarter included non-cash stock-based compensation of $15.9 million, as compared to $18.4 million last year. \n\n\n  Kodiak ended the quarter with $138.9 million of cash and cash equivalents, and said it believes it will support current and planned operations into 2026. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 13:41 ET (17:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}